Skip to main content
SpringerLink
Log in

Sucralfate

A Review of its Pharmacodynamic Properties and Therapeutic Use in Peptic Ulcer Disease

  • Drug Evaluations
  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Synopsis: Sucralfate1 is a basic aluminium salt of sulphated sucrose which is advocated for use in peptic ulcer disease. It is minimally absorbed after oral administration and is believed to act primarily at the ulcer site by protecting the ulcer from the effects of pepsin, acid and possibly bile salts.

Controlled therapeutic trials have demonstrated that sucralfate 1g 4 times daily is effective in increasing the rate of healing of duodenal and gastric ulcer over a period of 4 to 8 weeks. Trials comparing sucralfate and cimetidine have not found any significant difference in efficacy between the drugs in small numbers of patients. A dosage of 2g daily given prophylactically decreases the rate of recurrence of duodenal ulcers, but the efficacy of sucralfate in preventing relapse of gastric ulcers has yet to be clearly demonstrated.

Sucralfate is particularly well tolerated. Constipation, the most common side effect, occurs in 2% of patients.

Thus, sucralfate offers an effective and well tolerated alternative for the management of peptic ulcer disease.

Pharmacodynamic Studies: Animal studies have demonstrated a white paste-like substance that adheres selectively to ulcerated tissue after oral administration of sucralfate. The greater affinity of sucralfate for ulcer tissue than for healthy tissue has been confirmed in humans with gastric or duodenal ulcer who have undergone gastric resection or endoscopic biopsy.

Sucralfate decreases pepsin activity in vivo in rats and humans, and in diffusion cell experiments sucralfate-coated albumin was protected from peptic activity for over 3 hours. In other in vitro experiments sucralfate has been shown to adsorb bile salts, to decrease acid diffusion and have acid-buffering properties. However, sucralfate is minimally antacid.

Sucralfate decreases the frequency of ulcerous lesions in animals, caused by a variety of ulcerogenic substances and experimental techniques. In healthy subjects, aspirin-induced gastric mucosal damage was completely prevented in 8 of 12 subjects by prior administration of sucralfate 1g. The ability of sucralfate to limit gastric mucosal damage is also suggested by a rise in transmucosal electric potential difference following its administration in patients with gastric ulcer.

Pharmacokinetic Studies: Sucralfate is minimally absorbed after oral administration, with only 0.5 to 2.2% of a dose being recovered in the urine over a 4-day period after ingestion of 14C-labelled sucralfate. In animal distribution studies, 85 to 95% of a dose was located in the gastrointestinal tract.

Therapeutic Trials: Sucralfate has been compared with placebo and with cimetidine in patients with duodenal or gastric ulcer. Controlled trials have reported endoscopically confirmed healing of duodenal ulceration in 67 to 92% of patients treated with sucralfate 4g daily for 4 weeks and in 25 to 64% treated with placebo. The consumption of antacids has varied considerably between studies and may have contributed to the high placebo response rates in some studies.

Comparisons of sucralfate 4g and cimetidine 1 to 1.2g daily have generally been reasonably well designed, but have usually involved too few patients to be expected to detect any possible significant difference in efficacy between the drugs. Healing rates with sucralfate and cimetidine have been 66 to 80% and 73 to 75%, respectively, at 4 weeks.

Placebo-controlled studies in gastric ulcer have usually been less well designed than those in duodenal ulcer, although sucralfate 4 to 4.5g daily has been more effective than placebo in patients assessed endoscopically. In gastric, as in duodenal, ulcer, comparisons with cimetidine have included relatively small numbers of patients, and healing rates with both drugs have been similar after 6 or 8 weeks of treatment.

Sucralfate 1g twice daily administered prophylactically decreases the frequency of recurrence of duodenal ulcer relative to placebo over a period of 6 months. There was a tendency for 2g daily to be more effective than 1g daily in preventing duodenal ulcer relapse, but too few patients were included in each study group to permit any firm conclusion. Preliminary studies of sucralfate in the prevention of gastric ulcer recurrence are inconclusive. Further studies with different dosages of sucralfate in adequate numbers of patients are necessary to establish the efficacy of the drug in preventing recurrence of gastric ulcer and to determine the optimum dosage.

Side Effects: Few side effects are associated with administration of sucralfate 4g daily in the treatment of duodenal or gastric ulcer. Constipation is the most frequently reported complaint, which occurs in about 2% of patients. As sucralfate is a phosphate binder in patients with uraemia, it has potential to induce hypophosphataemia.

Dosage and Administration: The recommended adult dosage of sucralfate in the treatment of duodenal or gastric ulcer is 1g 3 times daily on an empty stomach, 1 hour before meals or 2 hours after meals, and 1g at bedtime. Treatment should be continued until the ulcer is healed, or if endoscopic reassessment is not possible, for up to 8 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Baron, J.H.; Gribble, R.J.N.; Holdsock, D.J. and Misiewicz, J.J.: Double-blind controlled trial of amylopectin sulfate (Depepsen) in the symptomatic treatment of duodenal ulcer. Gut 18: 723–724 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Bighley, L.D. and Giesing, D.: Mechanism of action studies of sucralfate, a new agent for treatment of ulcers (abstract). Gastroenterology 80: 1111 (1981).

    Google Scholar 

  • Borella, L.E.; Seethaler, K. and Lippman, W.: Sucralfate: Antipeptic, antiulcer activities and antagonism of gastric emptying. Arzneimittel-Forschung/Drug Research 29(I): 793–798 (1979).

    CAS  Google Scholar 

  • Brogden, R.N.; Carmine, A.A.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Ranitidine: A review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 24: 267–303 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Bruugsgard, A.; Elsbord, L. and Reinecke, V.: Bile acid binding properties of sucralfate; in Caspary (Ed.) Duodenal Ulcer, Gastric Ulcer: Sucralfate, A New Therapeutic Concept, pp. 28–31 (Urban and Schwarzenberg, Baltimore 1981).

    Google Scholar 

  • Caccese, W.J.; McKinley, M.J.; Kryle, L.S. and Bronzo, R.L.: Sucralfate and ulcer perforation. Correspondence. Annals of Internal Medicine 97: 619 (1982).

    PubMed  CAS  Google Scholar 

  • Caspary, W.F.: Binding of bile acids by sucralfate and cholestyramine; in Caspary (Ed.) Duodenal Ulcer, Gastric Ulcer: Sucralfate, A New Therapeutic Concept, pp. 32–88 (Urban and Schwarzenberg, Baltimore 1981a).

    Google Scholar 

  • Caspary, W.F.: The influence of glycocholic acid and sucralfate on transmural potential difference of the human stomach; in Caspary (Ed.) Duodenal Ulcer, Gastric Ulcer: Sucralfate, A New Therapeutic Concept, pp. 22–27 (Urban and Schwarzenberg, Baltimore 1981b).

    Google Scholar 

  • Classen, M.; Bethge, H.; Brunner, G.; Dirr, B.; Frotz, H.; Gaber, M.; Gail, H.; Grabner, R.; Hagenmüller, F.; Heinkel, K.; Kaess, H.; Kerstan, E.; Kuntzen, O.; Maier, K.; Meiderer, S.; Reichel, W.; Reissigl, H.; Schwambergen, K.; Seifert, E.; Thaler, H.; Weiss, W.; Wordenhoff, D. and Wotzka, R: Effect of sucralfate on peptic ulcer recurrence: A controlled double-blind multicentre study. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 61–68 (1983).

    Google Scholar 

  • Cocking, J.B.: A trial of amylopectin sulfate (SN-263) and propantheline bromide in the long-term treatment of chronic duodenal ulcer. Gastroenterology 62: 6–10 (1972).

    PubMed  CAS  Google Scholar 

  • Corinaldesi, R.; Piatico, A.; Cavalli, G.; Paparo, G.F.; Sacco, T. and Barbara, L.: Sucralfate and gastric cell loss induced by taurocholic acid in man. Drugs under Experimental and Clinical Research 8: 467–470 (1982).

    Google Scholar 

  • Fixa, B. and Komarkova, O.: Aluminium sucrose sulfate (Ulcermin) in ulcer therapy: Double-blind test. Paper presented at the Gastroenterology Society of the German Democratic Republic, Leipzig, Oct 9 (1973).

  • Giesing, D.H.; Lanman, R.C.; Dimmitt, D.C. and Runsen, D.J.: Lack of effect of sucralfate on digoxin pharmacokinetics (abstract). Gastroenterology 84 (No.5, part 2): 1165 (1983).

    Google Scholar 

  • Giesing, D.; Lonsaan, R. and Runsen, D.: Absorption of sucralfate in man. Gastroenterology 82: 1066 (1982).

    Google Scholar 

  • Guslandi, M.; Ballarin, E.; Cambielli, M.; Fesce, E. and Tittobello, A.: Sucralfate in the treatment of chronic superficial gastritis. Acta Therapeutica 7: 269–274 (1981).

    Google Scholar 

  • Guslandi, M.; Ballarin, E. and Tittobello, A.: Sucralfate in refractory duodenal ulcers. Abstract. Gut 24(5): A498 (1983).

    Google Scholar 

  • Harrington, S.J.; Schlegel, J.F. and Code, C.F.: The protective effect of sucralfate on the gastric mucosa of rats. Journal of Clinical Gastroenterology 3(Suppl. 2): 129–134 (1981).

    PubMed  CAS  Google Scholar 

  • Hentschel, E.; Schutze, K. and Dufek, W.: Controlled comparison of sucralfate and cimetidine in duodenal ulcer. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 31–35 (1983).

    Google Scholar 

  • Hirano, T. and Takagaki, Y.: Healing promotion effects of sucrose sulfate aluminium ester (Ulcermin) on acetic acid induced ulcer. Kiso-to-Rinsho (Clinical Report) 8(4): 1–12 (1974).

    Google Scholar 

  • Hollander, D.: Efficacy of sucralfate for duodenal ulcers: A multicentre, double-blind trial. Journal of Clinical Gastroenterology 3(Suppl. 2): 153–157 (1981).

    PubMed  CAS  Google Scholar 

  • Hollander, D.: A multicentre, double-blind trial of sucralfate in duodenal ulcer therapy. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 25–30 (1983).

    Google Scholar 

  • Hollander, D.; Tarnawski, A.; Gergely, H. and Zipser, R.D.: Sucralfate protection of gastric mucosa against alcohol-induced necroses: A prostaglandin mediated process? Abstract. Gastroenterology 84 (No. 5, part 2): 1190 (1983).

    Google Scholar 

  • Hurwitz, A.; Robinson, R.G.; Sheridan, M.; Quigley, M.; Hesterleo, E.J. and Getomer, S.: Prolongation of gastric emptying by sucralfate in man. Abstract. Gastroenterology 82: 1088 (1982).

    Google Scholar 

  • Ishimori, A.: Safety experience with sucralfate in Japan. Journal of Clinical Gastroenterology 3(Suppl. 2): 169–173 (1981).

    PubMed  CAS  Google Scholar 

  • Kairaluoma, M.I.; Ståheberg, M.; Laitinen, S.; Hentila, R. and Falovaara, P.: A placebo controlled, double blind, cross-over study of sucralfate in postcholecystectomy bile reflux gastritis. Abstract. Scandinavian Journal of Gastroenterology 18(Suppl. 86): 35 (1983).

    Google Scholar 

  • Kinoshita, H.; Kumaki, K.; Nakano, H.; Tsuyama, K.; Nagashima, R.; Okada, M. and McGraw, B.: Plasma aluminium levels of patients on long term sucralfate therapy. Research Communications in Chemical Pathology and Pharmacology 35: 515–518 (1982).

    PubMed  CAS  Google Scholar 

  • Lacz, J.P.; Drees, D.T. and Browne, R.K.: Sucralfate binding in cimetidine treated rats. Abstract. Gastroenterology 84 (No. 5, part 2): 1220 (1983).

    Google Scholar 

  • Lacz, J.P.; Groschang, A.G.; Giesing, D.H. and Browne, R.K.: The effect of sucralfate on drugs absorption in dogs. Abstract. Gastroenterology 82 (No. 5, part 2): 1108 (1982).

    Google Scholar 

  • Laitinen, J.; Aukee, S.; Miettinen, P.; Poikolainen, E.; Pääkkönen, M. and Sandström, R.: Sucralfate and cimetidine for gastric ulcer. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 49–51 (1983).

    Google Scholar 

  • Laitinen, S.; Kiviniemi, H.; Ståhlberg, M.; Hentilä, R. and Kairaluoma, M.: Sucralfate in the treatment of duodenal ulcer — an open, randomized study. Abstract. Scandinavian Journal of Gastroenterology 18(Suppl. 86): 42 (1983a).

    Google Scholar 

  • Laitinen, S.; Ståhlberg, M.; Kairaluoma, M.I.; Kiviniemi, H.; Pääkkönen, M.; Laitinen, J.; Poikolainen, E. and Aukee, S.: Sucralfate vs alginate plus antacid in reflux oesophagitis, a randomized, endoscopically controlled, double-blind multicentre study. Abstract. Scandinavian Journal of Gastroenterology 18(Suppl. 86): 43 (1983b).

    Google Scholar 

  • Landecker, K.D.; McCallum, E.M.; Fevre, D.I.; Green, P.H.R.; Kasumi, A. and Piper, D.W.: Effect of sodium amylosulfate (Depepsen) on the healing of duodenal ulcer. Gastroenterology 71: 723–725 (1976).

    PubMed  CAS  Google Scholar 

  • Leung, A.C.T.; Henderson, I.S.; Halls, D.J. and Dobbie, J.W.: Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. British Medical Journal 286: 1379–1381 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Libeskind, M.: Maintenance treatment of patients with healed peptic ulcer with sucralfate, placebo and cimetidine. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 69–70 (1983).

    Google Scholar 

  • McGraw, B.F.; Hesterlee, E.J.; Lanza, F.L. and Tesler, M.A.: In vitro and in vivo evaluations of a tableted antacid and sucralfate, a new antiulcer agent. American Journal of Gastroenterology 76: 412–415 (1981).

    PubMed  CAS  Google Scholar 

  • McHardy, G.G.: A multicenter, double-blind trial of sucralfate and placebo in duodenal ulcer. Journal of Clinical Gastroenterology 3(Suppl. 2): 147–162 (1981).

    PubMed  CAS  Google Scholar 

  • Marcus, R. and Watt, J.: Ulcerative disease of the colon in laboratory animals induced by pepsin inhibitors. Gastroenterology 67: 473–483 (1974).

    PubMed  CAS  Google Scholar 

  • Marks, I.N.; Wright, J.P.; Denyer, M.; Garisck, J.A.M. and Lucke, W.: Comparison of sucralfate with cimetidine in the short-term treatment of chronic peptic ulcers. South African Medical Journal 57: 567–573 (1980).

    PubMed  CAS  Google Scholar 

  • Marks, I.N.; Wright, J.P.; Lucke, W. and Girdwood, A.H.: Relapse rates following initial ulcer healing with sucralfate and cimetidine. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 53–56 (1983).

    Google Scholar 

  • Marks, I.N. and Girdwood, A.H.: Maintenance sucralfate and duodenal ulcer relapse — An interim report. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 71–73 (1983).

    Google Scholar 

  • Marks, I.N.; Lucke, W.; Wright, J.P. and Girdwood, A.H.: Ulcer healing and relapse rates after initial treatment with cimetidine or sucralfate. Journal of Clinical Gastroenterology 3(Suppl. 2): 163–165 (1981).

    PubMed  CAS  Google Scholar 

  • Martin, F.; Farley, A.; Gagnon, M. and Bensemana, D.: Comparison of the healing capacities of sucralfate and cimetidine in the short-term treatment of duodenal ulcer: A double-blind randomized trial. Gastroenterology 82: 401–405 (1982).

    PubMed  CAS  Google Scholar 

  • Martin, F.; Farley, A.; Gagnon, M.; Poitras, P. and Bensemana, D.: Short term treatment with sucralfate or cimetidine in gastric ulcer: Preliminary results of a controlled randomised trial. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 37–41 (1983a).

    Google Scholar 

  • Martin, F.; Gagnon, M.; Farley, H. and Poitras, P.: Comparative healing capacity of a mucosal protective agent, sucralfate, and cimetidine in short term treatment of gastric ulcer. A double blind randomised study of 41 patients. Abstract 98. Annals of the Royal College of Physicians and Surgeons of Canada 16(4): 332 (1983b).

    Google Scholar 

  • Masuda, M.; Taniguchi, M.; Takafuji, H.; Ulda, M.; Suzuki, S. and Morino, T.: Clinical effect of Ulcermin on peptic ulcer. Shinyto (Diagnosis and Therapy) 23: 93–98 (1970).

    Google Scholar 

  • Mayberry, J.F.; Williams, R.A.; Rhodes, J. and Lowrie, B.W.: A controlled clinical trial of sucralfate in the treatment of gastric ulcer. British Journal of Clinical Practice 32: 291–293 (1978).

    PubMed  CAS  Google Scholar 

  • Miyake, T.; Ariyoshi, J.; Suzaki, T.; Oishi, M.; Sakai, M. and Veda, S.: Endoscopic evaluation of the effect of sucralfate therapy and other clinical parameters on the recurrence rate of gastric ulcers. Digestive Diseases and Science 25: 1–7 (1980).

    Article  CAS  Google Scholar 

  • Miyoshi, A.; Moriga, M.; Kobayashi, M.; Suyama, T.; Kiguchi, Y. and Kishimoto, S.: Experimental and clinical studies on anti-pepsin preparations: I. Anti-pepsin and anti-ulcerogenic activities of sucrose sulfate. Japanese Archives of Internal Medicine 15: 419–434 (1968).

    PubMed  CAS  Google Scholar 

  • Möckel, W. and Hausding, P.: Behaviour of the transmural potential difference in the region of gastric ulcers in man under the influence of sucralfate; in Caspary (Ed.) Duodenal Ulcer, Gastric Ulcer Sucralfate, A New Therapeutic Concept, pp. 39–43 (Urban and Schwarzenberg, Baltimore 1981).

    Google Scholar 

  • Morris, D.L.; Youngs, D.; Burdon, D.W. and Keighley, M.R.B.: The influence of sucralfate or cimetidine on gastric juice pH, bacterial flora and mutagenicity (unpublished).

  • Moshal, M.G.; Spitaels, J.M. and Khan, F.: Sucralfate in the treatment of duodenal ulcers: A double-blind endoscopically controlled trial. South African Medical Journal 57: 742–744 (1980).

    PubMed  CAS  Google Scholar 

  • Moshal, M.G.; Spitaels, J.M. and Manion, G.L.: Double-blind placebo-controlled evaluation of one year therapy with sucralfate in healed duodenal ulcer. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 57–60 (1983).

    Google Scholar 

  • Mungall, D.; Talbert, R.L.; Phillips, C.; Jaffe, D. and Ludden, T.M.: Sucralfate and warfarin. Correspondence. Annals of Internal Medicine 98(4): 557 (1983).

    PubMed  CAS  Google Scholar 

  • Nagashima, R.: Basics of sucralfate. A review of certain Japanese studies; in Caspary (Ed.) Duodenal Ulcer, Gastric Ulcer: Sucralfate, A New Therapeutic Concept, pp. 13–18 (Urban and Schwarzenberg, Baltimore 1981c).

    Google Scholar 

  • Nagashima, R. and Hirano, T.: Selective binding of sucralfate to ulcer lesion. I. Experiments in rats with acetic acid-induced gastric ulcer receiving unlabelled sucralfate. Arzneimittel-Forschung/Drug Research 30(I): 80–83 (1980).

    CAS  Google Scholar 

  • Nagashima, R.; Hinohara, Y. and Hirano, T.: Selective binding of sucralfate to ulcer lesion. III. Experiments in rats with duodenal ulcers receiving 14C-sucralfate. Arzneimittel-Forschung/Drug Research 30(I): 88–91 (1980a).

    CAS  Google Scholar 

  • Nagashima, R.; Hinohara, Y.; Hirano, T.; Tohira, Y. and Kamiyama, H.: Selective binding of sucralfate to ulcer lesions. II. Experiments in rats with gastric ulcer receiving 14C-sucralfate or potassium 14C-sucrose sulfate. Arzneimittel-Forschung/Drug Research 30(I): 84–88 (1980b).

    CAS  Google Scholar 

  • Nagashima, R. and Yoshida, N.: Sucralfate, a basic aluminium salt of sucrose sulfate. I. Behaviour in gastroduodenal pH. Arzneimittel-Forschung 29: 1668–1676 (1979).

    PubMed  CAS  Google Scholar 

  • Nagashima, R.; Yoshida, N. and Terao, N.: Sucralfate, a basic aluminium salt of sucrose sulfate. II. Inhibition of peptic hydrolysis as it results from sucrose sulfate interaction with protein substrate, serum albumins. Arzneimittel-Forschung/Drug Research 30(I): 73–76 (1980c).

    CAS  Google Scholar 

  • Nagashima, R.: Development and characteristics of sucralfate. Journal of Clinical Gastroenterology 3(Suppl. 2): 103–110 (1981a).

    PubMed  CAS  Google Scholar 

  • Nagashima, R.: Mechanisms of action of sucralfate. Journal of Clinical Gastroenterology 3(Suppl. 2): 117–127 (1981b).

    PubMed  CAS  Google Scholar 

  • Nagashima, R.; Hosino, E.; Hinohara, Y.; Sakai, K.; Hata, S. and Nakano, H.: Effect of sucralfate on ethanol-induced gastric mucosal damage in the rat. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 17–20 (1983).

    Google Scholar 

  • Nakazawa, S.; Nagashima, R. and Samloff, I.M.: Selective binding of sucralfate to gastric ulcer in man. Digestive Diseases and Science 26: 297–300 (1981).

    Article  CAS  Google Scholar 

  • Pop, P.; Nikkels, R.E.; Thys, O. and Dorrestein, G.C.M.: Comparison of sucralfate and cimetidine in the treatment of duodenal and gastric ulcers. A multicentre study. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 43–47 (1983).

    Google Scholar 

  • Richardson, C.T.: Sucralfate. Annals of Internal Medicine 97: 269–271 (1982).

    PubMed  CAS  Google Scholar 

  • Roufail, W.M.: Pilot trial of a sulfated polysaccharide in the treatment of duodenal ulcer disease. Southern Medical Journal 72: 262–264 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Samloff, I.M.: Inhibition of peptic aggression by sucralfate. The view from the ulcer crater. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 7–11 (1983).

    Google Scholar 

  • Sasaki, H.; Hinohara, Y.; Tsunoda, Y. and Nagashima, R.: Binding of sucralfate to duodenal ulcer in man. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 13–14 (1983).

    Google Scholar 

  • Schenkein, J.P.; Liu, H.-L.; Watkins, J.B. and Shiau, Y.-F.: Bile salt binding properties of maalox, sucralfate and cholestyramine. Abstract. Gastroenterology 84 (No. 5, part 2): 1300 (1983).

    Google Scholar 

  • Sherman, R.A.; Hwang, E.R.; Walker, J.A. and Eiseinger, R.P.: Reduction in serum phosphorus due to sucralfate. American Journal of Gastroenterology 78: 210–211 (1983).

    PubMed  CAS  Google Scholar 

  • Smolow, C.R.; Bank, S.; Ackert, G.; Anfang, C. and Kranz, V.: Prevention of experimental duodenal ulcer in the rat by sucralfate. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 15–16 (1983).

    Google Scholar 

  • Steiner, K.; Buhring, K.U.; Faro, H.P.; Garbe, A. and Nowak, H.: Sucralfate: Pharmacokinetics, metabolism and selective binding to experimental gastric and duodenal ulcers in animals. Arzneimittel-Forschung/Drug Research 32: 512–518 (1982).

    CAS  Google Scholar 

  • Sun, D.C.H.: A controlled clinical trial of antacid, propantheline and amylopectin sulfate in duodenal ulcer. American Journal of Gastroenterology 60: 449–458 (1973).

    PubMed  CAS  Google Scholar 

  • Sun, D.C.H. and Ryan, M.L.: A controlled study on the use of propantheline and amylopectin sulfate (SN-263) for recurrences in duodenal ulcer. Gastroenterology 58: 756–761 (1970).

    PubMed  CAS  Google Scholar 

  • Sung, J.-L.; Yu, J.-Y.; Wang, T.-H.; Wang, C.-Y. and Chew, D.-S.: A placebo-controlled double-blind study of sucralfate in the short term treatment of duodenal ulcer. Scandinavian Journal of Gastroenterology 18(Suppl. 83): 21–24 (1983).

    Google Scholar 

  • Tarnawski, A.; Hollander, D.; Gergely, H. and Stachura, J.: Comparison of antacid, sucralfate, cimetidine and ranitidine in protection of gastric mucosa against ethanol injury. Abstract. Gastroenterology 84 (No. 5, part 2): 1331 (1983).

    Google Scholar 

  • Tesler, M.A. and Lim, E.S.: Protection of gastric mucosa by sucralfate from aspirin-induced erosions. Journal of Clinical Gastroenterology 3(Suppl. 2): 175–179 (1981).

    PubMed  CAS  Google Scholar 

  • Yamagata, S.; Ishimou, A. and Ogawa, N.: Clinical evaluation of drug efficacy on peptic ulcer by comparative, double-blind testing: Phase III study of N-acetyl-L-glutamine aluminium complex (KW 110). Rinsho Seijinhyo (Journal of Adult Disease) 4: 890 (1974).

    Google Scholar 

  • Zimmerman, H.; Bank, S.; Smolow, C. and Kranz, V.: Prevention of duodenal ulcers in the rat using a combination of ranitidine and sucralfate in subtherapeutic doses. Abstract 85. American Journal of Gastroenterology 77: 699 (1982).

    Google Scholar 

  • Zimmon, D.S.; Miller, G.; Cox, G. and Tesler, M.A.: Specific inhibition of gastric pepsin in the treatment of gastric ulcer. Gastroenterology 56: 19–23 (1969).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ADIS Drug Information Services, P.O. Box 34-030, Birkenhead, Auckland 10, New Zealand

    R. N. Brogden, R. C. Heel, T. M. Speight & G. S. Avery

Authors
  1. R. N. Brogden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. C. Heel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. M. Speight
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. S. Avery
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Various sections of the manuscript reviewed by: S. Bank, Long Island Jewish-Hillside Medical Center, New York, USA; M.J.S. Langman, Department of Therapeutics, University of Nottingham, United Kingdom; G. McHardy, Medical Center of New Orleans, New Orleans, USA; I.N. Marks, Gastrointestinal Clinic, University of Cape Town, Cape Town, South Africa; T. Miyake, Department of Geriatric Medicine, Kyoto University Hospital, Kyoto, Japan; D.W. Piper, Royal North Shore Hospital of Sydney, St Leonards, New South Wales, Australia; C.T Richardson, Gastroenterology Section, Veterans Administration Medical Center, Dallas, USA.

‘Antepsin’ (Ayerst, Farmos, Medipolar); ‘Carafate’ (Marion); ‘Iselpin’ (Ayerst); ‘Sulcrate’ (Nordic); ‘Ulcermin’ (Jaba); ‘Ulcerlmin’ (Chugai); ‘Ulcogant’ (Merck); ‘Ulsanic’ (Chugai, Du Pont).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brogden, R.N., Heel, R.C., Speight, T.M. et al. Sucralfate. Drugs 27, 194–209 (1984). https://doi.org/10.2165/00003495-198427030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198427030-00002

Search

Navigation